Meda expands Axorid collaboration

Meda expands the collaboration with the French development company Etypharm for the patented product Axorid. New territories, such as East Europe with Russia and Turkey, are now included in the collaboration. Previously, Meda held commercialization rights in Central and West Europe. Axorid consists of the well-known and broadly used substances; ketoprofen, a NSAID (Non Sterodial Anti-Inflammatory Drug) for the treatment of rheumatic disorders, and omeprazole, an acid reducing proton pump inhibitor (PPI). Axorid can prevent gastrointestinal side effects from use of NSAIDs. Axorid’s once-daily administration can also increase patient compliance.